Vitiligo

What changes during this transition

Non-segmental (generalized) vitiligo is the dominant presentation — symmetric, progressive, autoimmune-driven depigmentation patches on face, hands, feet, and trunk, with concurrent autoimmune overlay (Hashimoto's thyroiditis, T1DM, pernicious anemia, Addison's) common enough to be part of the standard workup. Segmental vitiligo is mechanistically distinct — unilateral, dermatomal distribution, more stable course, lower autoimmune burden, and routes through a different intervention sequence (surgical melanocyte transplantation, suction-blister grafting once stable, excimer laser). The standard workup includes Wood's-lamp examination, Vitiligo Area Scoring Index (VASI) or Vitiligo European Task Force (VETF) extent quantification, dermoscopy in atypical lesions, thyroid panel with TPO antibodies, fasting glucose, and screening for other autoimmune overlay where clinically indicated; biopsy is occasionally needed for atypical presentations. Standard-of-care has been reshaped by the July 2022 FDA approval of ruxolitinib cream (Opzelura, Incyte) — the first FDA-approved repigmentation therapy specifically for non-segmental vitiligo, based on the TRuE-V1 and TRuE-V2 Phase 3 trials showing meaningful facial and total-body VASI improvement at 24 and 52 weeks via topical JAK1/2 inhibition of the IFN-γ / CXCL9 / CXCL10 axis that drives the disease. That moved topical ruxolitinib ahead of off-label options as first-line topical repigmentation for facial and limited-extent disease, alongside the long-standing potent topical corticosteroid and topical calcineurin inhibitor (tacrolimus, pimecrolimus) options. Narrow-band UVB phototherapy remains the backbone for moderate-to-extensive disease, with excimer laser for localized lesions. Oral JAK inhibitors — upadacitinib and ritlecitinib — are in active vitiligo trials. The Pasricha oral mini-pulse corticosteroid protocol (Indian dermatology, decades of source-jurisdiction use) addresses rapidly progressing active disease. Surgical pathways (melanocyte-keratinocyte transplantation procedure, suction-blister epidermal grafting) are reserved for stable segmental and stable limited non-segmental disease. Camouflage with cosmetics and self-tanners is real symptomatic support; depigmentation with monobenzyl ether of hydroquinone is reserved for extensive disease where repigmentation is not feasible. Vitamin D status and concurrent autoimmune-overlay screening are part of the broader picture. The peptide library's role here is narrow and editorially specific. Melanotan-1 — pharmaceutical name afamelanotide, marketed as Scenesse by Clinuvel — is the only surfaced case: Tier 2 anchored by the Lim 2015 JAMA Dermatology randomized multicenter trial showing faster and more extensive repigmentation when afamelanotide implants were combined with narrow-band UVB phototherapy in non-segmental vitiligo, with the effect most pronounced in Fitzpatrick IV-VI skin types. Afamelanotide carries FDA (2019), EMA (2014), and TGA (2020) approval for erythropoietic protoporphyria — the vitiligo case is off-label everywhere but anchored by the published Phase 2 multicenter data plus the EPP regulatory weight, and the tier reflects the published trial signal capped by the absence of a Phase 3 vitiligo registration trial. Indian, Korean, and Chinese dermatology cohorts have published smaller confirmatory work on melanocortin-agonism repigmentation in darker-skinned populations, broadly consistent with the JAMA Dermatology signal. What is NOT surfaced and why. KPV (substrate-only) is the α-MSH 11-13 tripeptide whose published research register is anti-inflammatory work in colitis, not melanogenic activity — KPV does not retain meaningful MC1R agonism (the receptor afamelanotide's case rests on), and the community α-MSH-association framing extrapolates past where the research has gone. Thymosin alpha-1 (substrate-only) is Rule 6 non-propagation territory — the ~35-jurisdiction chronic hepatitis B registered indication does not propagate to vitiligo, and the immune-modulation direction (Th1 enhancement) is the opposite of what the autoimmune-depigmentation pathophysiology argues for. BPC-157 (substrate-only) has no published vitiligo research in any jurisdiction — the Sikiric Zagreb corpus is gastric mucosal and tendon-ligament work in rodent models, the mechanistic distance from those domains to melanocyte autoimmune destruction is not bridged in any source jurisdiction's publications, and WADA S0 status is a hard regulatory stop for tested athletes. GHK-Cu (substrate-only) sits in the cosmetic-melanogenesis literature register, not the autoimmune-depigmentation register — no published vitiligo trial in any jurisdiction, OTC-market noise creates user-comprehension overlap with the clinical conversation, and supporting melanocyte function without addressing the upstream autoimmune destruction is not the repigmentation mechanism story. All four exist as substrate for honest /ask answers when users probe — not as discovery options to elevate.